SUN Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited, established in 1983, is a leading Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Sun Pharma's extensive product portfolio encompasses generics, branded generics, specialty medications, over-the-counter (OTC) products, and antiretrovirals, catering to various therapeutic areas such as neuropsychiatry, cardiology, gastroenterology, and oncology.

As of the latest available data, Sun Pharma employs over 43,000 individuals globally. The company's shares are publicly traded on the Bombay Stock Exchange (BSE) under the ticker symbol 524715 and on the National Stock Exchange of India (NSE) under the ticker symbol SUNPHARMA. The promoter holding stands at 54.47%, with the remaining 45.53% held by public shareholders. For more information, visit their official website at sunpharma.com.

Sun Pharmaceutical Industries Limited operates a global network of manufacturing facilities, with 41 plants strategically located across India, the United States, and other international markets. These facilities are equipped to produce a wide array of pharmaceutical products, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company's manufacturing capabilities are supported by a dedicated team of over 2,900 R&D professionals, enabling the development of complex formulations and specialty products.

The leadership team at Sun Pharmaceutical Industries Limited is headed by Managing Director and Executive Chairman, Mr. Dilip S. Shanghvi. Mr. Aalok D. Shanghvi serves as the Chief Operating Officer and Head of Global Generics Research & Development. The Chief Financial Officer is Ms. Jayashree Satagopan, who also holds the position of Executive Vice President. Other key executives include Mr. Dheeraj Prasad Sinha, Executive Vice President and Chief Information Officer, and Mr. Suresh Kumar Rai, Chief Human Resources Officer.

Sun Pharmaceutical Industries Limited has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. In the U.S., the company has been operational since 1996, offering a range of generics, branded generics, and OTC products. Sun Pharma's U.S. headquarters are located in Princeton, New Jersey, with distribution and customer service teams across the country. In June 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Sun Pharma's facility in Dadra and Nagar Haveli, India, citing violations of Current Good Manufacturing Practice (CGMP) regulations. The company has also received approvals from the European Medicines Agency (EMA) and other regulatory bodies for various products, facilitating its market access in these regions.

Sun Pharmaceutical Industries Limited has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in over 100 countries, with a strong presence in regions such as Brazil, Mexico, Russia, Romania, and South Africa. Sun Pharma's commitment to improving access to medicines is evident through its participation in the World Health Organization's (WHO) prequalification program, which enables the company to supply quality-assured medicines to low- and middle-income countries.

Sun Pharmaceutical Industries Limited has strategically diversified its geographic presence to mitigate concentration risk and enhance global reach. The company's operations span across India, the United States, Europe, and emerging markets, allowing it to leverage growth opportunities in various regions. This diversification strategy enables Sun Pharma to balance market dynamics and regulatory challenges, positioning the company for sustained growth and resilience in the global pharmaceutical industry.

Sun Pharmaceutical Industries Limited's facilities are registered with the U.S. Food and Drug Administration (FDA), allowing the company to manufacture and distribute pharmaceutical products in the United States. The company has filed numerous Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) with the FDA, facilitating the approval of generic formulations. However, in June 2024, the FDA issued a warning letter to Sun Pharma's facility in Dadra and Nagar Haveli, India, citing violations of Current Good Manufacturing Practice (CGMP) regulations. The company has since taken corrective actions to address the identified issues and maintain compliance with FDA standards.

Sun Pharmaceutical Industries Limited's manufacturing facilities adhere to the World Health Organization's (WHO) Good Manufacturing Practices (GMP) and the European Union's GMP standards. The company's commitment to quality is demonstrated through its participation in the WHO prequalification program, which ensures that its products meet international quality standards. Additionally, Sun Pharma has obtained EU GMP certificates for its facilities, enabling the company to supply pharmaceutical products to European markets.

In India, Sun Pharmaceutical Industries Limited holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority. The company complies with the regulations set forth by the CDSCO and state drug controllers, ensuring the safety, efficacy, and quality of its pharmaceutical products. Sun Pharma also obtains export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT) for its international shipments, facilitating the export of its products to various countries.

In June 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Sun Pharmaceutical Industries Limited's facility in Dadra and Nagar Haveli, India, citing violations of Current Good Manufacturing Practice (CGMP) regulations. The FDA identified significant violations during an inspection conducted from December 4 to 15, 2023. The company has taken corrective actions to address the identified issues and maintain compliance with FDA standards.

Sun Pharmaceutical Industries Limited operates in a highly competitive pharmaceutical market, facing competition from both multinational and domestic companies. In the generic pharmaceutical sector, Sun Pharma competes with companies such as Teva Pharmaceutical Industries, Sandoz (a division of Novartis), and Mylan. In the specialty pharmaceutical segment, competitors include Bristol-Myers Squibb, Merck & Co., and Novartis. Sun Pharma's focus on complex formulations and specialty products differentiates it from competitors, allowing the company to capture market share in niche therapeutic areas.

Sun Pharmaceutical Industries Limited's key differentiators include its extensive product portfolio, which spans generics, branded generics, specialty medications, and over-the-counter products. The company's strong research and development capabilities, supported by a global network of R&D centers and a dedicated team of over 2,900 professionals, enable the development of complex formulations and specialty products. Sun Pharma's commitment to quality is demonstrated through its adherence to international manufacturing standards, including WHO and EU GMP certifications. Additionally, the company's strategic acquisitions, such as Taro Pharmaceuticals, have enhanced its presence in key markets like the United States.

Sun Pharmaceutical Industries Limited's current strategic direction focuses on expanding its presence in both generic and specialty pharmaceutical markets. The company's investments in research and development aim to drive innovation and address unmet medical needs, particularly in therapeutic areas such as dermatology, ophthalmology, and oncology. Sun Pharma's acquisition of Concert Pharmaceuticals in March 2023 and its increased stake in Pharmazz Inc. in June 2025 underscore its commitment to enhancing its specialty product portfolio. Looking ahead, the company is poised to leverage its diversified portfolio and global presence to achieve sustained growth and strengthen its position in the global pharmaceutical industry.

Sun Pharmaceutical Industries Limited has a strong track record as a pharmaceutical supplier, with a diverse product portfolio and a global presence in over 100 countries. The company's manufacturing facilities adhere to international quality standards, including WHO and EU GMP certifications, ensuring the safety and efficacy of its products. Sun Pharma's commitment to innovation is demonstrated through its substantial investment in research and development, with a dedicated team of over 2,900 professionals. The company's strategic acquisitions, such as Taro Pharmaceuticals, have enhanced its capabilities and market reach, particularly in the United States. Sun Pharma's consistent focus on quality, innovation, and global expansion positions it as a reliable and competitive supplier in the pharmaceutical industry.

Importers should verify the following certifications when sourcing products from Sun Pharmaceutical Industries Limited: